Key Takeaways for AbbVie Stock as of August 2026
- Debt Raise: AbbVie priced a $10 billion multi-tranche senior notes offering on August 5, funding roughly $9.93B of net proceeds toward its $10.9B Apogee Therapeutics acquisition set to close August 18.
- Street Split: Sixteen buys, eight outperforms, six holds, and one underperform make up Wall Street’s current rating split on AbbVie stock, with the mean target at $274, about 11% above the $246 close.
- Model Upside: TIKR pegs AbbVie stock at $359 by 2030, a 46% total return.
- Guidance Trim: Despite a Q2 beat of $3.65 adjusted EPS on $16.99B revenue, AbbVie narrowed full year guidance to $13.87-$14.07 from $13.91-$14.11 to absorb 14 cents of Apogee-related dilution.
AbbVie Stock’s $10 Billion Notes Sale Puts a Real Price on the Apogee Deal
AbbVie (ABBV) priced a $10 billion multi-tranche senior notes offering on August 5, with tranches running from a $500 million floating rate note due 2028 out to fixed-coupon notes maturing in 2066, carrying rates between 4.5% and 6.1%. Net proceeds land near $9.93 billion, and the bulk is earmarked for AbbVie’s $10.9 billion acquisition of Apogee Therapeutics, the immunology drugmaker it agreed to buy in June. The deal is set to close August 18, with leftover proceeds available for general corporate purposes, including possible debt repurchases. That detail matters for AbbVie stock because it turns an abstract dilution estimate into an actual, priced cost of capital.
CFO Scott Reents flagged this exact move on the July 31 earnings call, telling investors, “We have secured interim financing and expect to issue long-term debt in the coming months.” Five days later, AbbVie delivered on that promise. The notes sale confirms management is financing Apogee largely with debt rather than cash, which is why full year guidance already carries a 14 cent per share dilution hit tied to the acquisition.
The math behind that hit is clearer now. AbbVie is targeting a net leverage ratio of 2 times within two to three years of the deal closing. The higher coupon tranches, running 5% to 6.1% on the longest-dated notes, will weigh on interest expense through the back half of the decade even as Skyrizi and Rinvoq keep compounding.
AbbVie’s cash generation is already running ahead of that burden. Its NTM levered free cash flow yield has climbed to 7.5% as of August 7, up from 6.8% at the end of June and 6.3% a year ago, a trend that’s been building since the yield bottomed near 5.2% last October
AbbVie stock’s next test is whether immunology growth outruns that added interest burden faster than the Street currently prices in.
AbbVie Stock’s Q2 Beat Explains Why the Street Shrugged Off the Dilution
The debt raise lands against a backdrop of genuine operating strength. AbbVie posted second quarter adjusted EPS of $3.65, above the $3.61 Wall Street estimate, on revenue of $16.99 billion, ahead of the $16.76 billion consensus. Skyrizi sales climbed 24.4% to $5.51 billion and Rinvoq grew 24.5% to $2.53 billion, both beating estimates, while neuroscience revenue rose roughly 20%.
CEO Robert Michael called it “another excellent quarter with results once again exceeding our expectations.” He pointed to double-digit sales growth across the portfolio as the reason AbbVie can absorb the Apogee dilution without disturbing its underlying trajectory. Full year adjusted EPS guidance still narrowed to $13.87 to $14.07 from $13.91 to $14.11, a swap of $0.10 of operational upside for $0.14 of deal-related dilution. That’s a rounding error against the growth story, which is why AbbVie stock’s guidance cut barely dented sentiment.
Where Wall Street Stands on AbbVie Stock After the Rerating
Wall Street’s current split on AbbVie stock stands at 16 buys, 8 outperforms, 6 holds, and 1 underperform. Twenty-eight analysts publish price targets on the stock, with the mean sitting at $274, about 11% above the $246 close on August 7, and the median running higher at $280.
That mean target moved fast. It stood at $256 on June 30, then climbed $18 in five weeks even as the closing price slipped from $252 to $246 over the same stretch. Buy ratings held flat at 16 across that span, and holds stayed at 6, so the move reflects existing analysts raising targets rather than a wave of fresh upgrades. Coverage held steady near 28 analysts throughout, which tightens the read: this is conviction building among the same names already covering the stock, not new coverage arriving with a rosier view.
TIKR Values AbbVie Stock at $359, Pricing In Continued Immunology Growth
TIKR’s mid case model values AbbVie stock at $359 by December 2030, implying 46% total return from the current price of $246, or 9% annualized over 4.4 years.
That annualized rate sits above what a mega cap pharmaceutical name typically offers a buy-and-hold investor, especially one already trading near record highs alongside the rest of the healthcare sector.
The model’s target rests on Skyrizi and Rinvoq sustaining the growth rates AbbVie just posted, 24.4% and 24.5% respectively in the second quarter, long enough to absorb both the Apogee dilution and the interest cost on the new notes. The Street’s $274 mean target implies a smaller near-term gap, but the spread between that figure and the model’s $359, and between the model and the Street’s own $328 high target, shows how much of AbbVie stock’s long-run case still depends on execution years out rather than anything already reflected in the August 7 price.
Should You Invest in AbbVie Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABBV stock on TIKR for Free →
Looking for New Opportunities?
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
#Adessonews seleziona nella rete articoli di particolare interesse.
Se vuoi leggere l’articolo completo clicca sul seguente link
Gian Estrada
Source link
